

Practical Perspectives on the Current and Future Management of Immune Thrombocytopenia — What Happened at ASH 2025? Microlearning Activity 4

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What is the incidence of immune thrombocytopenia (ITP) secondary to the use of immune checkpoint inhibitors?**
 - a. 0.25%**
 - b. 2.5%
 - c. 5%
 - d. 7.5%
- 2. Most patients who develop ITP secondary to receiving immune checkpoint inhibitors recover with treatment.**
 - a. True**
 - b. False
- 3. Which of the following statements describes an important consideration for administering eltrombopag to a patient with ITP?**
 - a. Patients require dietary management to ensure proper absorption
 - b. Liver enzymes should be monitored closely
 - c. Both a and b**
 - d. Neither a nor b
- 4. Which of the following adverse events is a common side effect of fostamatinib?**
 - a. Thromboembolic events
 - b. Hypertension**
 - c. Cataracts